Medical Technologies

Medtronic receives FDA approval to expand the use of the "Hugo" robot in general surgery

Medtronic's "Hugo" robotic system has received a new clearance from the US Food and Drug Administration to include general surgery procedures, opening the door for its use in millions of surgeries annually.

2026-11-17
3 min read
14 views
certi.news Editorial Team
Medtronic receives FDA approval to expand the use of the "Hugo" robot in general surgery

Medtronic announced that its "Hugo" robotic system has received approval from the US Food and Drug Administration (FDA) for use in general surgery procedures. This expansion represents a major strategic step for the company in the robotic surgery market, as the new clearance covers specialties representing more than half of the soft tissue surgeries performed annually in the United States.

Scope of included surgical procedures

The new clearance includes a wide range of surgeries in the upper and lower abdomen, most notably:

  • Gallbladder removal.
  • Gastric bypass procedures (Roux-en-Y).
  • Abdominal hernia and inguinal hernia repair.
  • Small bowel resection.
  • Appendectomy.

According to company data, these procedures combined account for approximately 3.5 million surgeries annually in the US market alone, giving the "Hugo" system direct access to a huge segment of patients and hospitals that previously relied on competing solutions or traditional surgical methods.

Competition in the robotic surgery market

This announcement reinforces Medtronic's position as the first major medical technology company to successfully introduce a soft tissue robotic platform to the US market since the launch of the "da Vinci" system by Intuitive in 2000. Competition is currently heating up in this sector, as Johnson & Johnson obtained clearance for its "Ottava" system last July, while Stryker entered into an agreement to distribute the "Versius" robot in the United States.

Medtronic seeks to leverage its deep, decades-long expertise in open and laparoscopic surgical instruments, allowing surgeons to integrate its well-known technologies, such as the "LigaSure" vessel sealing device, into robot-assisted procedures, thereby facilitating the technical transition for medical teams.

What changes practically for hospitals?

The expansion of "Hugo's" scope of use aims to address capacity and access challenges in US hospitals. Instead of limiting the robot to specialized fields such as urology (where it received its first approval last December), hospitals can now use a single platform across multiple surgical departments, which improves the operational efficiency of expensive robotic equipment.

Company figures indicate that the growth of "Hugo" procedures globally is proceeding at twice the rate of the overall robotic surgery market, and the system is expected to cross the 50,000-surgery mark by the end of the current fiscal year, with general surgery topping the list of fastest-growing fields, surpassing urology and gynecology.

News source
c
Author

certi.news Editorial Team

In the same category

You may also like

View all news